Nanomedicine and Thrombolytics – Present and Future Partnership to Overcome Thrombotic Related Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (30 October 2021) | Viewed by 326
Special Issue Editors
Interests: targeted nanoparticles; drug delivery systems; neurovascular inflammation; thrombosis and hemostasis; gene therapy
Special Issue Information
Dear Colleagues,
Presently, ischemia and stroke caused by thrombosis are treated by using intravenous tissue plasminogen activator (IV-tPA) and thrombectomy approach. However, there are several drawbacks in using these approaches, as IV-tPA must be used within 4.5 h of disease onset, with possible major haemorrhagic effects. Moreover, thrombectomy is an invasive approach that may lead to vascular damage.
In order to improve the therapeutic window and prophylactic treatments on identified patients at risk of thrombosis-related diseases, nanomedicine has been employed in both new drug design and drug improvement or repurposing.
This Special Issue of Pharmaceutics will cover the developments in thrombolytics and nanomedicine intervention in thrombosis-related diseases as a new road to be explored for targeted and improved therapeutics.
Dr. Oscar Marcos-Contreras
Dr. Marco Domingues
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- thrombolytics
- nanomedicine
- antithrombotic
- pulmonary embolism
- stroke
- venous thromboembolism
